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A B S T R A C T
The purpose of this study was to investigate clinical aspects and quality of life (QOL) as risk factors for
depression in patients with epilepsy. One hundred and forty outpatients with a diagnosis of epilepsy who
were attending our epilepsy center participated. Patients anonymously ﬁlled out a questionnaire with
clinical data related to epilepsy. Depression level was evaluated by the Hamilton Depression Rating Scale-
17 (HAMD-17), and quality of life was evaluated by the Quality of Life in Epilepsy-31 (QOLIE-31). Thirty-
six patients with epilepsy suffered from depression (25.7%). Complex partial seizures (OR = 0.112) and
number of seizure types (OR = 3.773) were found to be clinical risk factors for depression. Low scores for
seizure worry (OR = 0.947) and social function (OR = 0.947) on the QOLIE-31 increased the probability of
depression in patients with epilepsy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The relationship between epilepsy and psychological distur-
bance has prompted numerous studies in recent years. Studies
have generally found a higher prevalence of affective disorders,
especially depression, in patients with epilepsy than among
healthy controls or people with other medical disorders. Epilepsy
patients with comorbid depression have signiﬁcantly more visits
to doctors, emergency departments, and hospitals than patients
with epilepsy. The Epilepsy Impact Survey has demonstrated that
health resource utilization in patients with epilepsy differs only by
depression status, not by seizure type or frequency, even in those
who have only few or minor seizures.1 Furthermore, depression
affects reported seizure severity. People with moderate to severe
depression report signiﬁcantly worse problems than those with no
depression with respect to severity of seizures as well as cognitive,
emotional, and physical aspects of seizure recovery.2
Depression in epilepsy patients can be classiﬁed according to
the onset of psychiatric symptoms and seizure occurrence into
ictal (the depressive symptoms are a clinical manifestation of the
seizure), periictal (symptoms precede and/or follow the seizure
occurrence), and interictal (symptoms occur independently of the
seizure occurrence).3 Interictal depression is the most frequently
recognized type of depression in patients with epilepsy.* Corresponding author at: Institute of Neurology, Huashan Hospital, Fudan
University, No.12, Wulumuqi Rd. (M), Shanghai 200040, China.
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1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2012.03.006In this study, we aimed to determine the frequency of interictal
depression among patients with epilepsy who attend our tertiary
epilepsy center clinic and analyze possible risk factors for
depression in patients with epilepsy.
2. Method
All patients analyzed in this study were outpatients attending
the epilepsy center in Huashan Hospital at Fudan University from
August 2007 to February 2008. All subjects had a conﬁrmed
diagnosis of epilepsy based on documented clinical data and EEG
monitoring, and were taking anti-epilepsy drugs (AEDs). The
classiﬁcation of epilepsy was deﬁned according to the ILAE
classiﬁcations published in 1989.4 Patients with cognitive im-
pairment who could not complete the questionnaires and those
with severe organic brain diseases were excluded from this study.
No patients were being treated with drugs that inﬂuence the
central nervous system, except for antiepileptic and anti-depres-
sive drugs. All patients signed an informed consent document as
required by the institutional ethics committee.
In the interictal period, at least 24 h after the last epileptic
seizure, all patients underwent the same research protocol. Data
were collected including patient age, gender, disease history,
physical and neurological examination results, age of onset,
duration of epilepsy, number of self-reported seizures in the
previous 6 months, and use of AEDs. The Hamilton Depression
Rating Scale (HAMD)5 and Quality of Life in Epilepsy-31 (QOLIE-
31)6 were administered. The classiﬁcation of patients as having
partial or generalized seizures was determined based on the
clinical features of seizures according to the International Leaguevier Ltd. All rights reserved.
Table 1
Patient characteristics and epilepsy details.
Number of subjects N 140
Gender
Male 70 (50%)
Female 70 (50%)
Mean duration of epilepsy (mean  SD) 10.9  10.7 (years)
Mean age of seizure onset (mean  SD) 22.8  15.8 (years)
Etiology N
Primary 65 (46.4%)
Secondary 75 (53.6%)
Seizure type N
Partial seizure
Simple partial seizure 7 (5%)
Complex partial seizure 49 (35%)
Secondarily generalized seizure 43 (30.7%)
Generalized seizure
Generalized tonic–clonic seizure 76 (52.3%)
Absent seizure 11 (7.9%)
Other seizure 4 (2.9%)
Seizure frequency N
<Once a month per seizure 74 (52.9%)
Once a month per seizure 66 (47.1%)
Number of anti-epilepsy drugs N
Monotherapy 94 (67.1%)
Polytherapy 46 (32.9%)
AEDs
Carbamazepine 83 (59.3%)
Valproic acid 37 (26.4%)
Clonazepam 12 (8.6%)
Topiramate 27 (19.3%)
Lamotrigine 11 (7.9%)
Oxcarbazepine 6 (4.3%)
Phenytoin 11 (7.9%)
Table 2
Analysis of epilepsy details of patients with and without depression.
Without
depression
N (%)
With
depression
N (%)
P value
Seizure type
Partial seizure
Simple partial seizure 4 (3.85) 3 (8.3) 0.287
Complex partial seizure 26 (25) 23 (63.9) 0.000*
Secondarily generalized
seizure
31 (29.8) 12 (33.3) 0.693
Generalized seizure
generalized tonic–clonic
seizure
60 (57.7) 16 (44.4) 0.169
Absent seizure 9 (8.65) 2 (5.6) 0.552
Number of seizure type 0.013*
One seizure type 73 (70.2) 17 (47.2)
2 seizure type 31 (29.8) 19 (52.8)
Seizure frequency 0.000*
<Once a month 66 (63.5) 8 (22.2)
Once a month 38 (36.5) 28 (77.8)
Number of AEDs 0.192
Monotherapy 73(70.2) 21 (58.3)
Polytherapy 31(29.8) 15 (41.7)
AEDs
Carbamazepine 63 (60.6) 20 (55.6) 0.597
Valproic acid 25 (24.0) 12 (3.3) 0.276
Clonazepam 7 (6.7) 5 (13.9) 0.186
Topiramate 19 (18.3) 8 (22.2) 0.604
Lamotrigine 8 (7.7) 3 (8.3) 0.902
Oxcarbazepine 5 (4.8) 1 (2.8) 0.604
Phenytion 7 (6.7) 4 (11/1) 0.400
Overall QOILE-31 scores 65.63  11.7 46.23  16.93 0.012*
Seizure worry scores 68.53  14.29 46.30  22.35 0.000*
Social function scores 72.45  13.9 41.46  21.66 0.000*
* P < 0.05.
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supported by the EEG ﬁndings.
Depression was diagnosed according to the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
criteria and assessed by the HAMD-17. The HAMD-17 includes 17
questions regarding depressed mood, feelings of guilt, suicide,
insomnia early (difﬁculty going to sleep), insomnia middle (waking
during the night), insomnia late (waking in early morning hours),
work and activities, psychomotor retardation, agitation, anxiety
(psychological), anxiety (somatic), somatic symptoms (gastroin-
testinal), somatic symptoms (general), sexual interest, hypochon-
driasis, loss of weight, and insight. The scale scores range from 0 to
54, with higher scores representing more severe depression. Scores
of 0–6 are considered normal, with scores of 7–17 considered a
mild, 18–24 a moderate, 19–22 a severe, and 24 a very severe
level of depression. Dimensions of quality of life in epilepsy were
assessed using the QOLIE-31, a self-report instrument that assesses
the major domains of health-related quality of life (HRQOL). This
instrument includes 31 questions divided into seven domains:
seizure worry, effects of epilepsy medications, emotional well-
being, energy/fatigue, cognitive function, social function, and
overall quality of life. Some scores are converted during the scoring
process so that higher scores always reﬂect better quality of life.
The Chinese version of HAMD-17 and QOLIE-31 scales both have
tested for validity and reliability before and proved to be
satisfactory for accession in Chinese context.8,9
The data analysis was performed with SPSS 11.5. Pearson’s chi
square test and a one-way ANOVA were used to evaluate
differences in categorical and quantitative data on epilepsy
patients with and without depression. Variables identiﬁed as
probably related to depression were included in a logistic
regression model. Summary statistics were reported as means 
SDs, and the statistical signiﬁcance level was set at P < 0.05.
3. Results
One hundred and forty patients (50% males) with a conﬁrmed
diagnosis of epilepsy were included in this study. Ages ranged from
15 to 71 years. Demographic characteristics of these patients are
listed in Table 1.
With respect to all patients, nearly half the cases were
classiﬁed as primary epilepsy (46.4%) and about half as secondary
epilepsy (53.6%). Of the 140 patients, 99 (70.7%) had simple or
complex partial seizures, 91 (65.0%) had generalized seizures,
and 50 (35.7%) suffered from two or more types. Forty-six
(32.9%) patients received AED polytherapy; 94 (67.1%) received
monotherapy.
Thirty-six (25.7%) patients with epilepsy had comorbid
depression, including 22 (61.1%) males and 14 (38.9%) females.
One female and one male (5.6%) had severe depression (HAMD-17
score >24). Among these patients, the duration of epilepsy was
2 months to 44 years, and the age of seizure onset ranged from 1 to
67 years. More than half the cases (21; 58.3%) were classiﬁed as
primary epilepsy. Seventeen (47.2%) patients presented with only
one seizure type, while 19 (52.8%) suffered from two or more
types. Fifteen (41.7%) patients received more than one AED. The
most commonly used drug was carbamazepine (20 patients;
55.6%), followed by valproic acid (12; 33.3%), topiramate (8;
22.2%), clonazepam (5; 13.9%), phenytion (4; 11.1%), and
lamotrigine (3; 8.3%).
The analysis of epilepsy patients with and without depression,
and the results of Pearson’s chi-square test and one-way ANOVA
between the two groups are shown in Table 2. There were no
signiﬁcant differences in gender, mean duration of epilepsy, mean
age of seizure onset, etiology, or number of concomitant AEDs.
Some clinical variables and QOILE-31 scores showing differences in
function Social 
scores (P=0.000) 
Seizure worry scores 
(P=0.030) 
Depression in patients with epilepsy 
seizure factors: Other 
QOILE-31 overall frequency, 
scores (P=NS) 
seizure of Amount 
types (P=0.049) 
partial Complex 
seizure (P=0.002) 
Fig. 1. Inﬂuence of analyzed factors on presence of depression in patients with epilepsy (NS: not statistically signiﬁcant).
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regression model, including number of seizure types, seizure
frequency, complex partial seizures, overall QOILE-31 scores,
seizure worry scores, and social function scores.
The results are presented in Fig. 1. The strongest predictor of
depression was number of seizure types (odds ratio (OR) = 3.773,
P = 0.049, B = 1.328). Seizure worry scores (OR = 0.947, P = 0.030,
B = 0.54), social function scores (OR = 0.947, P = 0.000, B = 0.10),
and complex partial seizure scores (OR = 0.112, P = 0.002,
B = 2.187) yielded a weaker predictive value. Other factors
showed a relationship to depression in univariate analysis, but
were excluded from logistic regression analysis.
4. Discussion
Patients with epilepsy have a higher lifetime prevalence of
depression than individuals without epilepsy.10 The prevalence of
depression in epilepsy ranges from 20% to 55% in patients with
recurrent seizures and from 3% to 9% in patients with controlled
epilepsy.3 In our patient population, 25.7% had depression, which
is similar to ﬁndings in other studies.3,11 We also found that the
frequency of severe depression requiring treatment was similar to
that reported in previous studies.12,13 Gender, duration of epilepsy,
age of onset, and etiology of epilepsy had no association with
depression.
Many previous studies have found that more seizure types,
more seizure frequency, and more AED usage are associated with a
higher prevalence rate of depression in patients with epilepsy.14,15
In this study, we obtained similar data. The number of seizure
types was a positive predictor for depression, and seizure
frequency was signiﬁcantly different between those with and
without depression according to Pearson’s chi-square test. It is
possible that more seizure types and more seizure frequency
reﬂect a more severe course of epilepsy and more difﬁcult-to-treat
seizures. However, amount of AEDs only represented a trend, with
an insigniﬁcant difference between the patients with and without
depression. This may be attributable to the limited amount of data.
If more patients were brought into this study, a signiﬁcant
difference might be found.
Our study conﬁrmed that complex partial seizures are a positive
risk factor for depression in patients with epilepsy. This type of
seizure is usually recurrent and has been associated with
depression.16 Furthermore, most complex partial seizures are
originated from the temporal and frontal lobes, which have been
identiﬁed as positive predictors for depression in patients with
epilepsy.17,18 In both depression and epilepsy, atrophy of the
mesial temporal structures and changes in the amygdala (in
temporal epilepsy), prefrontal cortex, cingulate gyrus, and white
matter (in frontal epilepsy) have been reported.19 This sharedunderlying pathology may predispose patients to both complex
partial seizures and depression. There is a decrease in 5-HT1A
receptor binding in patients with depression,20 and similar
abnormalities in 5-HT1A receptor binding have been identiﬁed
in patients with temporal lobe epilepsy.21,22 Furthermore, patients
with temporal lobe epilepsy and depression exhibit a signiﬁcantly
more pronounced reduction in 5-HT1A receptor binding than
patients with either single disease.23
Patients with epilepsy and comorbid depression have signiﬁ-
cant neuropsychological, psychiatric, and social impairments that
limit their education, employment opportunities, and possibilities
for marriage. Furthermore, depression is recognized as a predictor
of poor QOL in patients with epilepsy.2,24,25 Our study showed that
the subscales of seizure worry and social function on the QOLIE-31
were independent negative predictors of depression in patients
with epilepsy. Thus, not only does depression negatively affect QOL
in patients with epilepsy, but low QOL scores, especially related to
aspects of seizure worry and social function, increase the
possibility of comorbid depression. This ﬁnding indicates a
bidirectional relationship between depression and QOL in these
patients. Thus, we should attend more to QOL in patients with
epilepsy, not only in regard to seizures, but also to reduce the
incidence of comorbid depression.
Seizure severity (based on a medical evaluation) may not
coincide with seizure worry (subjective evaluation of seizure
situations). Self-evaluation of what it means to be sick, to have
seizures, and to control one’s seizures are parameters of personal
QOL.26 Souza concluded that the perception patients have about
their condition affects their mood more than the condition itself.27
This suggests that the more worried patients are about seizures,
the more depressed they may be, even if the seizure severity does
not change.
The presence of mood disorders has an inﬂuence on the choice
of AEDs. Carbamazepine, valproic acid, and lamotrigine have mood
stabilizing properties. Carbamazepine and valproic acid have
antimanic effects, and lamotrigine has antidepressant effects in
patients with bipolar disorder. In our study, there was not a
signiﬁcant difference in depression in patients on these AEDs
compared with those not taking them, consistent with other
studies.15 Data demonstrating the efﬁcacy of these medications in
the management of depression are limited and more supportive of
their use as adjuncts to other psychotropic medications than as
monotherapy.28
A major limitation of our study is that our institution was a
tertiary epilepsy center. Our patients probably had more seizure
frequency, took more AEDs, were more difﬁcult to treat and
accordingly, had a higher rate of depression. Studies with a
community-based design should be conducted to determine a
relatively realistic depression rate in patients with epilepsy.
T. Zhao et al. / Seizure 21 (2012) 367–370370The ﬁndings in this study suggest that at tertiary epilepsy
centers such as ours in China, the prevalence rate of depression is
as high as in other countries.3,11 Therefore, it is very important for
doctors to be aware of this life-threatening comorbid symptom,
routinely evaluate depression in patients with epilepsy, and
diagnose and treat comorbid depression when needed.
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